RxDoctor Payments Data

Jennifer Palamara, MD

Neurology · Benzonia, MINPI 1194738468

Payments from drug & device makers

$923in general payments, 2019–2025

Across 46 payments — averaging $20.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$244
  • Teva Pharmaceuticals USA, Inc.$143
  • Johnson & Johnson$92
  • Axsome Therapeutics, Inc.$81
  • AbbVie$76
  • Alkermes, Inc.$68
  • plus $219 from 7 others

What the payments were for

  • Food & beverage$75882%
  • Education$16618%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$923 in reported general payments places this provider in the 40th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$16,427
Medicare patients
52
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$169,487
VraylarCariprazine Hcl89$134,960
Abilify MaintenaAripiprazole50$129,180
Invega TrinzaPaliperidone Palmitate14$110,377
Invega SustennaPaliperidone Palmitate38$106,316
IngrezzaValbenazine Tosylate11$89,996
RexultiBrexpiprazole37$51,387
CaplytaLumateperone Tosylate12$21,040
TrintellixVortioxetine Hydrobromide25$11,388
Quetiapine Fumarate ErQuetiapine Fumarate141$6,005
Vilazodone Hcl57$4,272
Lurasidone Hcl25$4,252
Atomoxetine Hcl44$4,038
Clozapine OdtClozapine36$3,278
Desvenlafaxine Succinate ErDesvenlafaxine Succinate82$3,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$92$216,69352 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$244$180,56687 claims
Teva Pharmaceuticals USA, Inc.Austedo$143$169,48711 claims
AbbVieVraylar$76$134,96089 claims
Neurocrine Biosciences, Inc.Ingrezza$13$89,99611 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$66$21,04012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$26$11,38825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 652 neurology providers in Michigan.

Other neurology in Benzonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →